Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02808364 : Personalized Cellular Vaccine for Recurrent Glioblastoma (PERCELLVAC2)
PhasePhase 1/Phase 2
AgesMin: 18 Years Max: 65 Years
Eligibility
Inclusion Criteria:

- Recurrent glioblastoma grade IV

- Patients at the age of 18-65.

- Patients undergo tumor resection.

- Patients with Karnofsky scores > or =70

- Patients with normal range of hematologic and metabolic test results.

- Patients must have no corticosteroids treatment at least one week before vaccination.

- Patients capable of understanding the study and signed informed consent.

Exclusion Criteria:

- Breast feeding females.

- Pregnant women.

- Infectious diseases HIV, HBV, HCV

- Documented immunodeficiency

- Documented autoimmune disease

- Any serious or uncontrolled medical or psychiatric conditions, for example, severe
pulmonary, cardiac or other systemic disease.

- Patient inability to participate as determined by PI discretion.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02808364      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740